Genscript Biotech Reports 2022 Annual Results* : vimarsana.c

Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% Revenue of the Group for the year ended December 31,...

Related Keywords

China , Nanjing , Jiangsu , Japan , Sherry Shao , Japan Ministry Of Health , Genscript Nanjing Co Ltd , Revenue Of The Group , Genscript Group , Non Cell Therapy Achieved , Adjusted Net Profit , Script Biotech , Legend Biotech , Reporting Period , European Commission , Results Announcement , Genscript Nanjing Co , Ltd ,